v3.24.3
Collaboration, License, and Other Agreements - Sanofi, Antibody Narrative (Details) - Sanofi Collaboration Agreement, Antibody - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2024
Disaggregation of Revenue [Line Items]    
Percentage share of profits to reimburse collaborating party   20.00%
Contingent reimbursement obligation   $ 1,810.0
Sales Milestone Five    
Disaggregation of Revenue [Line Items]    
Revenue, remaining performance obligation, variable consideration amount $ 50.0  
Levels of twelve month sales at which sales milestone payments would be received $ 3,000.0  
Period for achieving sales target for milestone payment, rolling basis 12 months  
Minimum    
Disaggregation of Revenue [Line Items]    
Percentage of trial costs required to be funded by collaborating party   80.00%
Percentage share of profits to reimburse collaborating party   30.00%
Maximum    
Disaggregation of Revenue [Line Items]    
Percentage of trial costs required to be funded by collaborating party   100.00%
Percentage share of profits to reimburse collaborating party   50.00%